Izzedine H - Search Results

1

Management of hypertension in angiogenesis inhibitor-treated patients.

Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, Khayat D, Spano JP. Izzedine H, et al. Ann Oncol. 2009 May;20(5):807-15. doi: 10.1093/annonc/mdn713. Epub 2009 Jan 15. Ann Oncol. 2009. PMID: 19150949 Free article. Review.

2

New challenges in kidney cancer therapy: sunitinib.

Izzedine H, Billemont B, Thibault F, Rixe O. Izzedine H, et al. Ann Oncol. 2007 Jul;18 Suppl 9:ix83-6. doi: 10.1093/annonc/mdm298. Ann Oncol. 2007. PMID: 17631600 Free article. Review. No abstract available.

3

[Angiogenesis inhibitor therapies: focus on hypertension and kidney toxicity].

Izzedine H. Izzedine H. Bull Cancer. 2007 Nov;94(11):981-6. Bull Cancer. 2007. PMID: 18055316 Review. French.

4

Pharmacokinetics of sunitinib in hemodialysis.

Izzedine H, Etienne-Grimaldi MC, Renée N, Vignot S, Milano G. Izzedine H, et al. Ann Oncol. 2009 Jan;20(1):190-2. doi: 10.1093/annonc/mdn626. Epub 2008 Sep 18. Ann Oncol. 2009. PMID: 18801884 Free article. No abstract available.

5

Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment: case report.

Gombos A, Izzedine H, Besse B, Massard C, Brocheriou I, Bahleda R, Soria JC. Gombos A, et al. Among authors: izzedine h. Invest New Drugs. 2010 Feb;28(1):102-5. doi: 10.1007/s10637-009-9247-3. Epub 2009 Apr 3. Invest New Drugs. 2010. PMID: 19343274

6

Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase I trial.

Bahleda R, Massard C, Soria JC, Izzedine H, Cohen A, Ederhy S. Bahleda R, et al. Among authors: izzedine h. Invest New Drugs. 2010 Jun;28(3):350-2. doi: 10.1007/s10637-009-9252-6. Epub 2009 Apr 25. Invest New Drugs. 2010. PMID: 19396400

7

QT interval prolongation among patients treated with angiogenesis inhibitors.

Ederhy S, Cohen A, Dufaitre G, Izzedine H, Massard C, Meuleman C, Besse B, Berthelot E, Boccara F, Soria JC. Ederhy S, et al. Among authors: izzedine h. Target Oncol. 2009 Apr;4(2):89-97. doi: 10.1007/s11523-009-0111-3. Epub 2009 May 6. Target Oncol. 2009. PMID: 19418112 Review.

8

Reversible cardiogenic shock following 5-fluorouracil infusion.

Ferté C, Gomez Roca C, Loriot Y, Bahleda R, Moldovan C, Cohen A, Izzedine H, Soria JC, Ederhy S. Ferté C, et al. Among authors: izzedine h. Invest New Drugs. 2010 Aug;28(4):531-3. doi: 10.1007/s10637-009-9271-3. Epub 2009 Jun 5. Invest New Drugs. 2010. PMID: 19499187

9

A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma.

Etienne-Grimaldi MC, Renée N, Izzedine H, Milano G. Etienne-Grimaldi MC, et al. Among authors: izzedine h. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Nov 1;877(29):3757-61. doi: 10.1016/j.jchromb.2009.09.011. Epub 2009 Sep 17. J Chromatogr B Analyt Technol Biomed Life Sci. 2009. PMID: 19797000

10

Thrombotic microangiopathy related to anti-VEGF agents: intensive versus conservative treatment?

Izzedine H, Sène D, Hadoux J, Gharbi C, Bourry E, Massard C, Soria JC. Izzedine H, et al. Ann Oncol. 2011 Feb;22(2):487-90. doi: 10.1093/annonc/mdq743. Ann Oncol. 2011. PMID: 21278225 Free article. Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

271 results

Search Page

Filters